Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out if spironolactone, a drug that blocks the action of aldosterone, can make the blood vessels work better in people with obesity. The investigators also want to find out whether spironolactone causes changes in levels of insulin and markers of inflammation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Mineralocorticoids; Spironolactone

Criteria

Inclusion Criteria:

1. Age 18-70 years

2. Good health as evidenced by history and physical exam

3. Body Mass Index (BMI): >30 kg/m2 and <45 kg/m2

Exclusion criteria:

1. Medical illnesses other than treated hypothyroidism

2. Blood Pressure (BP) >135/85 or systolic BP <90 mm Hg

3. Hepatic disease (transaminase > 3 times normal)

4. Renal impairment (Creatinine clearance <60 ml/min)

5. Baseline serum Potassium (K) >5.0 mmol/L

6. History of drug or alcohol abuse

7. Allergies to spironolactone

8. Participation in any other concurrent clinical trial

9. Women using oral contraceptives within the last 3 months